General eCQM Information
|CMS Measure ID||CMS646v1|
Percentage of patients initially diagnosed with nonmuscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.
|Initial Population||All patients initially diagnosed with T1, Tis or high grade Ta nonmuscle invasive bladder cancer and a qualified encounter in the measurement period.|
Equals Initial population
Immunosupppressed patients, includes HIV and immunocompromised state.
Immunosuppressive drug therapy.
Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease.
Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging.
Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series.
BCG is initiated within 6 months of the bladder cancer staging and overlaps the measurement period.
Unavailability of BCG
|Measure Steward||Oregon Urology|
|Measure Scoring||Proportion measure|
|Measure Type||Process measure|
A higher score is the preferred result and indicates better quality
Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.
The BCG dose can be full or partial and can be from any lot or manufacturer.
This eCQM is a patient-based measure.
|Meaningful Measure||Appropriate Use of Healthcare|